封面
市场调查报告书
商品编码
1133510

全球疟疾疫苗市场2022~2029

Global Malaria Vaccines Market - 2022-2029

出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 约2个工作天内

价格

本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

主要驱动因素是疟疾流行率上升、各种生物技术和製药公司加大研发力度,以及政府主导的疟疾疫苗意识提高,这些有望推动市场增长。我来了。

预计全球疟疾流行率上升将推动市场增长。

全球疟疾发病率上升将在预测期内提振市场。例如,根据世界卫生组织 (WHO) 的数据,2022 年全球将观察到约 2.41 亿例病例,其中将记录 627 万例死亡。 2020 年,非洲地区再次成为全球疟疾负担的最高份额,该地区占疟疾病例的 95%,死亡人数的约 96%。在撒哈拉以南非洲,每年约有 260,000 名 5 岁以下儿童死于疟疾,它仍然是儿童疾病和死亡的主要原因。

该疫苗由葛兰素史克 (GSK) 和疟疾疫苗倡议 (MVI) 在盖茨家庭基金会的资助下开发,称为 RTS,S。该疫苗是世界卫生组织 (WHO) 于 2021 年 10 月推荐的第一种在儿童中“广泛使用”的疟疾疫苗。

R21/Matrix-M 是目前最有效的疟疾疫苗,在第一项研究中证实有 77% 的功效。它是第一个符合世界卫生组织要求的有效率75%或以上的疟疾疫苗的疫苗。与牛津大学、伦敦卫生和热带医学学院、肯尼亚医学研究所、印度血清研究所、Novavax 和布基纳法索 Nanoro 健康科学研究所合作开发。与 RTS,S 疫苗相比,这种 R21 疫苗使用了更高百分比的环子孢子蛋白 (CSP) 抗原。

与疟疾疫苗製造相关的限制因素阻碍了市场增长

缺乏开发人员、缺乏传统市场以及製造疫苗反寄生虫的技术困难可能是疟疾疫苗生产面临的挑战。疾病控制和预防中心于 2021 年 10 月发布的一份报告指出,“疟疾寄生虫的遗传复杂性有数千种潜在抗原。”与已经有有效疫苗接种的疾病相比,接触疟原虫不会带来终身□□免疫。 “因此,从上述陈述来看,我们预计市场在预测期内将受到阻碍。

全球疟疾疫苗市场报告将提供对大约 40 多个市场数据表、45 多个数字和 200 多页(大约)的访问。

内容

第一章市场研究方法和范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第 4 章市场动态

  • 市场影响因子
    • 驱动程序
      • 生物製药公司和製药公司的研发活动
    • 约束因素
      • 与疟疾疫苗相关的限制
    • 商机
    • 影响分析

第五章行业分析

  • 波特五力
  • 未满足的需求
  • 流行病学
  • 供应链分析
  • 监管分析

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按传染病类型

  • 恶性疟原虫
  • 按蚊种类
  • 间日疟原虫
  • P. 疟疾
  • 其他

第 8 章疫苗类型

  • 红细胞
  • 红细胞生成促进剂
  • 多抗原
  • 其他

第 9 章,最终用户

  • 医院
  • 专科诊所
  • 零售药房
  • 其他

第 10 章按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 11 章竞争格局

  • 主要发展和战略
  • 公司份额分析
  • 产品基准
  • 值得关注的重点公司列表

第 12 章公司简介

  • 葛兰素史克 (GSK)
    • 公司概况
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • Sanaria
  • Nobelpharma
  • The Swiss Serum Institute
  • VLP Therapeutics LLC
  • Serum Institute of India
  • CellFree Sciences
  • Novavax
  • Bharat Biotech
  • Kenya medical research institute

第 13 章疟疾疫苗全球市场DataM

简介目录
Product Code: DMPH884

Market Overview

Malaria Vaccines Market size was valued at US$ 33.29 million in 2021 and is estimated to reach US$ 327.41 million by 2029, growing at a CAGR of 31.85% during the forecast period (2022-2029).

Malaria an intermittent and remittent fever caused by a protozoan parasite that invades the red blood cells and is transmitted by mosquitoes in many tropical and subtropical regions and leads to severe illness in both pediatrics and adults. Malaria often causes severe disease, including shivering chills, high fevers, and flu-like symptoms. Humans are infected by four different types of malaria parasites Plasmodium falciparum, species of Anopheles, P. ovale, P. vivax, and P. malaria. Malaria vaccines are considered amongst the most important modalities for the prevention of malaria disease and the reduction of malaria transmission.

Market Dynamics

The major driving forces are the rising incidence of malaria cases, increase in research and development by various biotechnology or pharmaceutical companies and increasing government initiatives for malaria vaccines awareness are expected to drive market growth.

The rising incidences of malaria globally is expected to drive the market growth

The rising incidences of malaria cases globally are boosting the market over the forecast period. For instance, according to the World Health Organisation, around 241 million cases were observed globally out of which 6,27,000 deaths were recorded in 2022. African region again shows highest malaria burden share globally in 2020, 95% malaria cases with around 96% deaths were accounted by this region. In sub-Saharan Africa, it continues to be greatest cause of sickness and mortality in children as it claims around 260,000 lifes of African kids every year with age around 5 years or below.

The most recent recombinant vaccine to be created was RTS,S, which was created by GlaxoSmithKline (GSK) and Malaria Vaccine Initiatives (MVI) with funding from the the Gates Family Foundation. The vaccine is the 1st malaria vaccine to be recommended for "wide use" in children by World Health Organization in October 2021.

R21/Matrix-M is currently the most efficient malaria vaccine, with first studies showing 77% efficacy. This is the first vaccination that satisfies the WHO's requirement for a malaria vaccine to have at least a 75% effectiveness rate. The University of Oxford, London School of Hygiene and Tropical Medicine, Kenya Medical Research Institute, Serum Institute of India, Novavax and Institute of Research in Health Sciences in Nanoro, Burkina Faso collaborated to create it. Compared to the RTS,S vaccine, this R21 vaccine utilizes a larger proportion of the circumsporozoite protein (CSP) antigen.

The limitations associated with the malaria vaccines production will hamper the growth of the market

The scarcity of developers, traditional market's lack and the technical difficulty of creating a vaccine counter parasite can be the challenges for the production of a malaria vaccine. In October 2021 the Centre for diseaese control and prevention published a report where they stated that "The genetic complexity of malaria parasites results in thousands of possible antigens. Encounter with plasmodium parasites does not provide lifetime immunity, in contrast to diseases for which there are already effective vaccinations." Therefore, from the above statements, the market is expected to get hampered in the forecast period.

Segment Analysis

The plasmodium falciparum segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The plasmodium falciparum segment is expected to boost the global malaria vaccine market, owing to the increased number of incidences leading to growing research activities. Due to the high incidence by Plasmodium falciparum malaria infection cases, it is anticipated to maintain a dominating position in the worldwide malaria vaccines market in forecasr period. For instance, plasmodium falciparum infection is responsible for more than 90% of malaria fatality worldwide, according to data from the National Center for Biotechnology Information published in August 2021, and thus continues to pose a serious threat to public health on a global scale. RTS,S/AS01 is the potential vaccine for P. falciparum malaria prevention that has undergone the most extensive testing; it targets immune responses against primary circumsporozoite protein (PfCSP) that covers the infecting sporozoite's surface.

Geographical Analysis

North America region holds the largest market share of the global malaria vaccines market

North America dominates the market for malaria vaccine and is expected to show a similar trend over the forecast period owing to the rising incidences of malaria and the rapid research and development of innovative, advanced vaccines development for malaria. According to Pan America Health Organization (PAHO) report 2022, around 600,000 cases of malaria were reported in 2020 by 18 endemic American countries. That shows reduction of 26% from last year. In 2018 Paraguay, got malaria-free certification and El Salvador also received malaria-free certification in 2021.

Ongoing research and development activities are expected to boost the market. For instance, in Dec 2021, VLP Therapeutics Inc., biotech company that is based in United States collaborated for infectious disease vaccination manufacturing and distribution with Nobelpharma Ltd.

Competitive Landscape

The malaria vaccines market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market are Major key players in malaria vaccines market are GlaxoSmithKline Biologicals (GSK), the Swiss Serum Institute, WRAIR, Sanaria, BioNTech, Nobelpharma, CellFree Sciences, Sumaya Biotech, VLP Therapeutics LLC, Bharat Biotech, Serum Institute of India, Novavax, Kenya medical research institute. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the Malaria Vaccines market globally. For instance, in Sep 2021, Serum Institute of India subsidiary, Serum Institute Life Sciences announced its alliance with Biocon Biologics Limited. Under this alliance they will manufacture and commercialize variety of vaccines and antibodies targeting infectious diseases.

In Jun, 2022, BioNTech announced the initiation of construction of its first African facility for manufacturing of m-RNA Vaccine. They will manufacture m-RNA vaccines along with the development of malaria vaccine candidate.

GlaxoSmithKline Biologicals:

Overview:

GSK is a multinational biopharmaceutical business with the aspiration and mission to combine talent, science, and technology in order to conquer disease. They concentrate on four treatment fields: cancer, immunology, oncological disorders, and HIV. Prioritizing vaccination and specialty drug innovation will maximize the growing prospects for disease prevention and treatment.

Product Portfolio:

RTS, S/AS01 (Mosquirix): This is a recombinant vaccine for malaria that was created utilizing DNA from outer glycoprotein of the malaria parasite known as P. falciparum, a part of the hepatitis B virus, and an adjuvant to stimulate the immune system. Mosquirix is its name for commercial purpose. Elevated antibody titers that stop the parasite from invading the liver and helps to avoid infection.

Key Developments: In Oct 2021, Mosquirix vaccine became the first malarial vaccine to be recommended for "wide use" in children by World Health Organization.

The global malaria vaccines market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Table of Contents

1. Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The increase in research and development by biopharmaceutical and pharmaceutical companies
    • 4.1.2. Restraints:
      • 4.1.2.1. Limitations associated with the malaria vaccines
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces
  • 5.2. Unmet Needs
  • 5.3. Epidemiology
  • 5.4. Supply chain Analysis
  • 5.5. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type of infectious agents

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of infectious agents
    • 7.1.2. Market Attractiveness Index, By Type of infectious agents
  • 7.2. Plasmodium Falciparum
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Species of Anopheles
  • 7.4. P. vivax
  • 7.5. P. malaria
  • 7.6. Others

8. By Type of Vaccines

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of vaccines
    • 8.1.2. Market Attractiveness Index, By Type of vaccines
  • 8.2. Erythrocytic
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Pre erythrocytic
  • 8.4. Multi antigen
  • 8.5. Others

9. By End user

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 9.1.2. Market Attractiveness Index, By End user
  • 9.2. Hospitals
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Specialty Clinics
  • 9.4. Retail Pharmacy
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of infectious agents
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Vaccines
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of infectious agents
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of vaccines
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of infectious agents
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of vaccines
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of infectious agents
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of vaccines
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of infectious agents
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of vaccines
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking
  • 11.4. List of Key Companies to Watch

12. Company Profiles

  • 12.1. GlaxoSmithKline Biologicals (GSK)
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Sanaria
  • 12.3. Nobelpharma
  • 12.4. The Swiss Serum Institute
  • 12.5. VLP Therapeutics LLC
  • 12.6. Serum Institute of India
  • 12.7. CellFree Sciences
  • 12.8. Novavax
  • 12.9. Bharat Biotech
  • 12.10. Kenya medical research institute

LIST NOT EXHAUSTIVE

13. Global Malaria Vaccines Market- DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us